IP Library Granted Patent US 9,034,869
Granted Patent B2
US 9,034,869 · App. 13/789,606 · Granted May 19, 2015

Bridged heterocyclic compounds and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,034,869
App. No.
13/789,606
Granted
May 19, 2015
Kind
B2
Abstract

This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic[4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

Claims (66)

1. A compound, or a salt thereof, wherein the compound is selected from the group consisting of compounds:

Compound #

Structure

115

116

117

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

163

164

165

2. A compound of the formula (F-1):

wherein:

R 1 is H, hydroxyl, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 2 -C 8 alkenyl, substituted or unsubstituted C 2 -C 8 alkynyl, perhaloalkyl, acyl, acyloxy, carbonylalkoxy, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, C 1 -C 8 perhaloalkoxy, alkoxy, aryloxy, thioalkyl, substituted or unsubstituted amino, acylamino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aminosulfonyl, sulfonylamino, sulfonyl or carbonylalkylenealkoxy;

each R 2 and R 10 is independently H, hydroxyl, alkoxyl or substituted or unsubstituted C 1 -C 8 alkyl;

each R 3a and R 3b is independently H, substituted or unsubstituted C 1 -C 8 alkyl, halo, cyano, nitro, hydroxyl, alkoxy, amino, substituted amino, cycloalkyl, acylamino or acyloxy or R 3a and R 3b are taken together to form a cycloalkyl or a carbonyl moiety;

p is 1 or 2;

each X 7 , X 8 , X 9 and X 10 is independently N or CR 4 ;

each R 4 is independently H, hydroxyl, nitro, cyano, halo, C 1 -C 8 perhaloalkyl, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 2 -C 8 alkenyl, substituted or unsubstituted C 2 -C 8 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, C 1 -C 8 perhaloalkoxy, C 1 -C 8 alkoxy, aryloxy, carboxyl, thiol, carbonylalkoxy, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, thioalkyl, substituted or unsubstituted amino, acylamino, aminoacyl, aminocarbonylamino, aminocarbonyloxy, aminosulfonyl, sulfonylamino, sulfonyl, carbonylalkylenealkoxy, alkylsulfonylamino or acyl;

R 11 and R 12 are independently H, C 1 -C 8 alkyl, C 1 -C 8 perhaloalkyl, carboxy, carbonylalkoxy, or taken together with the carbon atoms to which they are attached to form a substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl or substituted or unsubstituted heterocyclyl moiety or are taken together to form a bond, thereby providing an acetylenyl moiety; indicates the presence of either an E or Z double bond configuration when R 11 and R 12 are independently H or C 1 -C 8 alkyl; and

Q is a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or an unsubstituted heterocyclyl, unsubstituted amino, substituted amino, alkoxy, aminoacyl, acyloxy, carbonylalkoxy, aminocarbonylalkoxy, acylamino, carboxy, alkynyl or cyano;

or a salt thereof.

3. The compound of claim 2 , or a salt thereof, wherein R 1 is methyl, each R 2 , R 3a , R 3b and R 10 is H, p is 1, X 9 is CR 4 where R 4 is halo or methyl, each X 7 , X 8 and X 10 is CH, R 11 is H, R 12 is methyl and Q is substituted phenyl.

4. The compound of claim 2 , wherein the compound is of the formula (F-2):

or a salt thereof.

5. The compound of claim 4 , or a salt thereof, wherein R 1 is methyl, each R 2 , R 3a , R 3b and R 10 is H, p is 1, X 9 is CR 4 where R 4 is halo or methyl, each X 7 , X 8 and X 10 is CH and Q is substituted pyridyl.

6. The compound of claim 2 , or a salt thereof, wherein R 11 is H and Q is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

7. The compound of claim 6 , or a salt thereof, wherein R 12 is H or methyl.

8. The compound of claim 7 , or a salt thereof, wherein R 1 is methyl, p is 1, and X 9 is CR 4 where R 4 is halo or methyl.

9. A pharmaceutical composition comprising a compound according to any one of claims 1 , 2 - 5 and 6 - 8 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10. A kit comprising a compound according to any one of claims 1 , 2 - 5 and 6 - 8 or salt thereof and instructions for using said compound or salt thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 28, 2016
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: MEDIVATION PROSTATE THERAPEUTICS, INC.; MEDIVATION TECHNOLOGIES, INC.
Reel/Frame 040181/0177 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 4, 2015
From: MEDIVATION TECHNOLOGIES, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 036553/0925 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2015
From: HUNG, DAVID T.; PROTTER, ANDREW ASHER; CHAKRAVARTY, SARVAJIT; JAIN, RAJENDRA PARASMAL
To: MEDIVATION TECHNOLOGIES, INC.
Reel/Frame 034855/0420 →